NT-rådet har beslutat att ALS-medicinen Tofersen kan användas i Sverige för en begränsad grupp patienter med en specifik mutation i SOD1-genen och snabbare försämring av sjukdomen, efter tidigare rekommendationer om att avstå från generell användning. #ALS #Tofersen #Sverige
Pam Belluck's article details Amanda Sifford's experience with a new A.L.S. therapy called tofersen, which has shown promising results in improving her lung function and overall health despite the challenges of a severe neurological condition that has afflicted her family. #ALS #Neurology #ClinicalTrials #US #CA
Pam Belluck's article highlights the experience of Amanda Sifford, an A.L.S. patient undergoing the newly approved therapy tofersen in Miami, which has led to notable improvements in her breathing and mobility, raising hope for others with this debilitating disease despite its severe side effects and the challenges of treating various A.L.S. symptoms. #ALS #NeurodegenerativeDisorders #GeneTherapy #US #CA
Pam Belluck's article follows Amanda Sifford, a 58-year-old A.L.S. patient, who experiences a significant improvement in her condition after receiving tofersen, a newly approved therapy targeting a specific genetic mutation, despite battling severe side effects and the ongoing challenges of the disease, offering hope for a treatable future for A.L.S. patients. #ALS #GeneticTherapy #Neurology #US #CA #BG
Pam Belluck's article chronicles the inspiring journey of Amanda Sifford, a 58-year-old A.L.S. patient, who, after receiving the recently FDA-approved genetic therapy tofersen, experienced remarkable improvements in her breathing and overall condition, defying the typical progression of the disease and igniting hope for others affected by A.L.S. #ALS #Neurology #TreatmentInnovation #US #CA
